Studies on pyrazinoylguanidine

Pharmacology

Volumn 54, Issue 5, 1997, Pages 241-255

  Follansbee, Mark H ^a   Beyer, Karl H ^a   Grifflth, James W ^a   Vesell, Elliot S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Captopril; Diabetic nephropathy; Hydrochlorothiazide; Pyrazinoylguanidine; STZ rats

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; CAPTOPRIL; GUANIDINE DERIVATIVE; HUMAN INSULIN; HYDROCHLOROTHIAZIDE; INSULIN; PROTEIN; PYRAZINE DERIVATIVE; PYRAZINOYLGUANIDINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; KIDNEY FUNCTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; STREPTOZOCIN DIABETES; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GUANIDINES; HYDROCHLOROTHIAZIDE; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MOLECULAR WEIGHT; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; STREPTOZOCIN;

EID: 0030794289     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139492     Document Type: Article

References (27)

1. A-Rahim YI. Beyer KH Jr. Vesell HS: Studies on pyrazinoylguanidine. Characterization of metabolic effects in diabetic rats. Pharmacology 1996;52:135-144.
2. A-Rahim YI. Beyer KH Jr, Vesell ES; Studies on pyrazinoylguanidine. Comparative effects on glucose and lipid metabolism in streptozotocin-induccd diabetic rats. Pharmacology 1996:52:145-152.
3. Chambers CE, Vesell ES. Helm C, Passananti GT. Beyer KH Jr: Pyrazinoylguanidine: Anlihypcnensivc. hypocholestérolémie, and renin effects. J Clin Pharmacol 1992:32: 1128-1134.
4. Ritz E. Fliscr D. Sicbels M: Diabetic nephropathy; in Massry. Glassock (ed): Textbook of Nephrology. Baltimore, Williams & Wilkins. 1995. pp 894-912.
5. Reddi AS, Camerini-Davalos RA: Diabetic nephropathy-An update. Arch Intern Med 1990:150:31-43.
6. Viberti JC. Keen H: The patterns of proteinuria in diabetes mellitus. Relevance to pathogenesis and prevention of diabetic nephropathy. Diabetes 1984:33:686-692.
7. Viberti GC. Jarrct RJ. Mahmud U. Hill RD. Argvropoulos A. Keen H: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;i: 1430-1432.
8. Marczcwski K, Krawczyk W, Szcze-panski L, Jarosz M. Rozyc P. Grzywna R, Piotrowski M, Stepniak C. Raszewski G, Klimek K: Erhöhte Ausscheidung von glomcrulärcn und tubulären Hamprotcir.cn bei Tvp-II-Diabetikern. Patienten mit chronischer Polyarthritis und koronarer Herzkrankheit ohne manifeste Nephropathie. Nieren Hochdruckkr 1996;24:570-572.
9. Pfleiderer S. Zimmerhack LB, Kinne R. Manz F. Schuler G. Brandis M: Renal proximal and distal tubular function is attenuated in diabetes mellitus type I as determined by the renal excretion of alpha-1-glycoprotein and Tamm-Horsfall protein. Clin Invest 1993; 71:972-977.
10. Galaske RG. Van Licw JB. Feld LG: Filtration and reabsorption of endogenous low-molecular-weight protein in the rat kidney. Kidney Int 1979;16:394-403.
11. Pennell J P. Meinking TL: Pattern of urinary proteins in experimental diabetes. Kidnev Int 1982;21:709-713.
12. Papper S, Andrews MD: Diabetic glomerulosclerosis. Contrib Nephrol. Basel. Karger. 1995, vol 7. pp 97-113.
13. Chcvillc NF: Ultrastructural Pathology: An Introduction to Interpretation. Ames. Iowa Slate Press. 1994. pp 367-368.
14. Makino H. Yamasaki Y. Hironaka K, Ota Z: Glomerular extracellular matrices in rat diabetic glomerulopathy by scanning electron microscopy. Virchows Arch [B] 1992:62:19-24.
15. Rakicntcn N. Rakienten ML. Nad-kami MV: Studies on the diabetic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963;29:91-98.
16. The Microalbuminuria Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996:39:587-593.
17. Rasch R: Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. Diabetologia 1980:18:413-416.
18. Pesce MA. Strande CS: A new micromethod for déterminât ion of protein in cerebrospinal fluid and urine. ClinChem 1973:19:1265-1267.
19. Diezel W, Koppcrschlagcr G. Hofmann E: An improved procedure for protein staining in polyacrylamide gels with a new type of Coomassie brilliant blue. Anal Biochcm 1972; 48:617-620.
20. Beyer KH Jr. Mattis PA. Patch EA. Russo HF: Para-aminohippuric acid: Its pharmacodynamic actions. J Pharmacol Ther 1945:84:136.
21. McDowell EM. Trump BF: Histologic fixatives suitable for diagnostic light and electron microscopy. Arch Pathol Lab Med 1976:100:405-414.
22. Beyer KH Jr. Gelarden RT. Vary JE. Brown LE, Vescll ES: Novel multivalent effects of pyrazinoyl-guanidine in patients with azotemia. Clin Pharmacol Ther 1990:47:629-638.
23. Ellis D. Lloyd C. Becker DJ. Forrest KY-Z, Orchard TJ: The changing course of diabetic nephropathy: Low-density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria. Am J Kidney Dis 1996;27:809-818.
24. Krolewski AS, Warram JH. Christlieb AR: Hypercholesterolemia-A determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994: 45(suppl 45): 125-135
25. Mulec H. Johnson SA. Wiklund O. Bjorck S: Cholesterol: A renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993;22:196-201.
26. Lam KSL, Cheng IKP. Janus ED. Pang RWC: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabcto-logia 1995:38:604-609.
27. Parving H-H: Letter to the editors: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabctologia 1996:39: 367.